3 results
Primary Objective:Proof of concept study designed to document the safety and feasibility of adjuvant treatment with the PICSO Impulse system in patients with acute anterior ST-segment elevation myocardial infarction (STEMI) treated with primary PCI…
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…